Anagrelide
Anagrelide
Definition
A synthetic quinazoline derivative, Anagrelide reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)
Also known as ANAGRELIDE — per NCIT
Also identified as
- ATC L01XX35 per RXNORM
- NCIT NCIT:C28825 per NCIT
- SCTID 108976008 per RXNORM
- SCTID 372561005 per RXNORM
- UNII K9X45X0051 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Acquired polycythemia vera | may treat | MEDRT · Public domain (U.S. Government work) |
| Thrombocytosis disease | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Bone marrow | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.